Ketamine Treatment for Mood Disorders

被引:0
|
作者
Klise, Andrew [1 ]
Lerner, Brian [1 ]
Ettensohn, Marc F. [1 ]
Levine, Steven P. [1 ]
机构
[1] Actify Neurotherapies, 3214 Charles B Root Wynd,Suite 203, Raleigh, NC 27612 USA
关键词
MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; INTRAVENOUS KETAMINE; SUICIDAL IDEATION; RESISTANT; AUGMENTATION; MECHANISMS; EFFICACY; ADULTS;
D O I
10.3928/00485713-20180315-01
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Ketamine is a glutamate modulator that increases synaptogenesis at sub-anesthetic doses in animal models. Studies examining ketamine's use in major depressive disorder have yielded large effect sizes for depression symptom reduction, depression remittance, and an independent reduction of suicidal ideation. Although there is more evidence supporting ketamine for the treatment of unipolar depression, studies examining ketamine's use in bipolar depression have also been positive, with no evidence that ketamine induces a "switch" from depression to mania. Although ketamine is sometimes used in conjunction with electroconvulsive therapy (ECT), outstanding evidence indicates little to no enhancement of ECT outcome. A standard dose of intravenous ketamine for depression is 0.5 mg/kg over 40 minutes; current lines of investigation are probing optimal dose and maintenance regimens.
引用
收藏
页码:175 / 179
页数:5
相关论文
共 50 条
  • [1] Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
    G Sanacora
    H Heimer
    D Hartman
    S J Mathew
    M Frye
    C Nemeroff
    R Robinson Beale
    [J]. Neuropsychopharmacology, 2017, 42 : 1179 - 1181
  • [2] Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
    Sanacora, G.
    Heimer, H.
    Hartman, D.
    Mathew, S. J.
    Frye, M.
    Nemeroff, C.
    Beale, R. Robinson
    [J]. NEUROPSYCHOPHARMACOLOGY, 2017, 42 (06) : 1179 - 1181
  • [3] A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
    Sanacora, Gerard
    Frye, Mark A.
    McDonald, William
    Mathew, Sanjay J.
    Turner, Mason S.
    Schatzberg, Alan F.
    Summergrad, Paul
    Nemeroff, Charles B.
    [J]. JAMA PSYCHIATRY, 2017, 74 (04) : 399 - 405
  • [4] The Evidence for Ketamine in Mood Disorders
    Mathew, Sanjay J.
    [J]. PSYCHIATRIC ANNALS, 2020, 50 (02) : 44 - 45
  • [5] Copper and Impulsivity in Ketamine Treatment for Treatment-Resistant Mood Disorders
    Slupski, Jakub
    Cubala, Wieslaw Jerzy
    Gorska, Natalia
    Slupska, Anita
    Galuszko-Wegielnik, Maria
    [J]. PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, 2021, 31 (03) : 353 - 357
  • [6] Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress
    Kritzer, Michael D.
    Mischel, Nicholas A.
    Young, Jonathan R.
    Lai, Christopher S.
    Masand, Prakash S.
    Szabo, Steven T.
    Mathew, Sanjay J.
    [J]. ANNALS OF CLINICAL PSYCHIATRY, 2022, 34 (01) : 33 - 43
  • [7] Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress
    Kritzer, Michael D.
    Mischel, Nicholas A.
    Young, Jonathan R.
    Lai, Christopher S.
    Masand, Prakash S.
    Szabo, Steven T.
    Mathew, Sanjay J.
    [J]. ANNALS OF CLINICAL PSYCHIATRY, 2021, 33 (04) : E10 - E20
  • [8] KETAMINE AND NMDA RECEPTOR MODULATION FOR TREATMENT-RESISTANT MOOD DISORDERS
    Mathew, Sanjay J.
    [J]. BEHAVIOURAL PHARMACOLOGY, 2013, 24 : E8 - E9
  • [9] Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Women
    Gagne, Collin
    Piot, Alexandre
    Brake, Wayne G.
    [J]. FRONTIERS IN PSYCHIATRY, 2022, 12